Philadelphia, PENNSYLVANIA2 Active Studies

Myasthenia Gravis Clinical Trials in Philadelphia, PENNSYLVANIA

Find 2 actively recruiting myasthenia gravis clinical trials in Philadelphia, PENNSYLVANIA. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
24
Enrolling

Recruiting Myasthenia Gravis Studies in Philadelphia

About Myasthenia Gravis Clinical Trials in Philadelphia

Myasthenia gravis is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles responsible for breathing and movement. It occurs when communication between nerves and muscles is disrupted. Treatment includes medications that improve neuromuscular transmission and immunosuppressive therapies.

There are currently 2 myasthenia gravis clinical trials recruiting participants in Philadelphia, PENNSYLVANIA. These studies are seeking a combined 24 participants. Research is being sponsored by Janssen Research & Development, LLC, Alexion Pharmaceuticals, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myasthenia Gravis Clinical Trials in Philadelphia — FAQ

Are there myasthenia gravis clinical trials in Philadelphia?

Yes, there are 2 myasthenia gravis clinical trials currently recruiting in Philadelphia, PENNSYLVANIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Philadelphia?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Philadelphia research site will contact you about next steps.

Are clinical trials in Philadelphia free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Philadelphia studies also compensate for your time and travel.

What myasthenia gravis treatments are being tested?

The 2 active trials in Philadelphia are testing new therapies including novel drugs, biologics, and treatment approaches for myasthenia gravis.

Data updated March 2, 2026 from ClinicalTrials.gov